Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
Phase 2 Terminated
3 enrolled 10 charts
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
Phase 2 Terminated
1 enrolled 7 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
Phase 2 Terminated
13 enrolled 5 charts
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
39 enrolled 10 charts
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
Phase 2 Terminated
30 enrolled 4 charts
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Phase 3 Terminated
58 enrolled 18 charts
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Phase 1/2 Terminated
1 enrolled 8 charts
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Phase 1 Terminated
9 enrolled 8 charts
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Phase 2 Terminated
2 enrolled 5 charts
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Phase 1/2 Terminated
10 enrolled 13 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Phase 2 Terminated
9 enrolled 13 charts
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
Phase 2 Terminated
34 enrolled 12 charts
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
Phase 2 Terminated
7 enrolled 10 charts
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Phase 2 Terminated
8 enrolled 11 charts
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
Phase 2 Terminated
5 enrolled 4 charts
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Phase 2 Terminated
42 enrolled 8 charts